drugset
drugset / Trial / NCT04144036

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

NCT04144036 ↗

Phase 1 Completed 12 enrolled Sameem M. Abedin, MD
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a single-center Phase I study to determine the maximum tolerated dose and safety of Neihulizumab for the treatment of Minnesota standard-risk aGVHD. Patients undergoing allogeneic transplant with either a myeloablative or non-myeloablative conditioning regimen, and recipients of all donor sources will be enrolled to this trial.

Timeline

Start
2020-12-14
Primary completion
2023-04-20
Completion
2024-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Neihulizumab Monoclonal antibody 3 mg/kg —
Subject Neihulizumab Monoclonal antibody 6 mg/kg —
Subject Neihulizumab Monoclonal antibody 9 mg/kg —

Indications

acute graft versus host disease